Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 0.77 mg (equivalent: estradiol, qty 0.75 mg) - drug delivery system, transdermal - excipient ingredients: isopropyl palmitate; polyethylene terephthalate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). estraderm mx 25 is not indicated for the prevention of post-menopausal bone mineral density loss. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.54 mg (equivalent: estradiol, qty 1.5 mg) - drug delivery system, transdermal - excipient ingredients: isopropyl palmitate; polyethylene terephthalate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and sectoin 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 7.6 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 3.8 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; glyceryl laurate; ethyl oleate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.56 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.17 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.78 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.39 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Ireland - English - HPRA (Health Products Regulatory Authority)

syn vet-pharma ireland limited - progesterone - vaginal delivery system - 1.0 gram(s) - progesterone